Abstract
The costs and benefits of a HIV/AIDS PMTCT program in a Mozambican city were calculated. The provision and non-provision of infant feeding formula were considered, along with voluntary counselling and testing, and anti-retroviral treatment with Nevirapine. Costs were calculated in monetary units and benefits as deaths averted and disability-adjusted life years. The UNAIDS cost-effectiveness tool for evaluating ARV drug and substitute feeding interventions was used. The costs of the program were compared with the costs of treating HIV-infected children. With no infant feeding formula, there would be a total savings of US$5242 and a negative cost per DALY of US$1.53 without infant feeding formula. With formula, net annual costs would be US$141,268 and cost per DALY US$38.69. Citywide, each year 132 infant deaths would be averted by use of Nevirapine and eight averted by the breastmilk replacement program. All program options have reasonable cost-effectiveness ratios.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
